The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksShield Thera Regulatory News (STX)

Share Price Information for Shield Thera (STX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 2.35
Bid: 2.30
Ask: 2.40
Change: -0.05 (-2.08%)
Spread: 0.10 (4.348%)
Open: 2.45
High: 2.50
Low: 2.35
Prev. Close: 2.40
STX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

28 Jun 2017 10:37

RNS Number : 4170J
Shield Therapeutics PLC
28 June 2017
 

TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi
 

1. Identity of the issuer or the underlying issuerof existing shares to which voting rights areattached: ii

SHIELD THERAPEUTICS PLC

2 Reason for the notification (please tick the appropriate box or boxes):

An acquisition or disposal of voting rights

ü

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments

An event changing the breakdown of voting rights

ü

Other (please specify):

3. Full name of person(s) subject to thenotification obligation: iii

W. HEALTH LP

4. Full name of shareholder(s)  (if different from 3.):iv

HARGREAVE HALE NOMINEES LIMITED

5. Date of the transaction and date onwhich the threshold is crossed orreached: v

28th JUNE 2017

6. Date on which issuer notified:

28th JUNE 2017

7. Threshold(s) that is/are crossed orreached: vi, vii

49% to 48%

 

8. Notified details:

A: Voting rights attached to shares viii, ix

Class/type ofshares

if possible usingthe ISIN CODE

Situation previousto the triggeringtransaction

Resulting situation after the triggering transaction

NumberofShares

NumberofVotingRights

Numberof shares

Number of votingrights

% of voting rights x

Direct

Direct xi

Indirect xii

Direct

Indirect

 

GB00BYV81293

54,062,901

54,062,901

56,008,541

56,008,541

48.24%

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financialinstrument

Expirationdate xiii

Exercise/Conversion Period xiv

Number of votingrights that may beacquired if theinstrument isexercised/ converted.

% of votingrights

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi

Resulting situation after the triggering transaction

Type of financialinstrument

Exercise price

Expiration date xvii

Exercise/Conversion period xviii

Number of voting rights instrument refers to

 

% of voting rights xix, xx

 

 

 

Nominal

Delta

Total (A+B+C)

Number of voting rights

Percentage of voting rights

56,008,541

48.24%

 

9. Chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held, if applicable: xxi

 

Shares held by Hargreave Hale Nominees Limited

 

Proxy Voting:

10. Name of the proxy holder:

N/A

11. Number of voting rights proxy holder will cease to hold:

N/A

12. Date on which proxy holder will cease to hold voting rights:

N/A

13. Additional information:

14. Contact name:

Matthew Edwards (on behalf of W. Health L.P.)

15. Contact telephone number:

0203 620 2000

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLFPMLTMBJTMJR
Date   Source Headline
18th Feb 20222:00 pmRNSPrice Monitoring Extension
17th Feb 20229:05 amRNSSecond Price Monitoring Extn
17th Feb 20229:00 amRNSPrice Monitoring Extension
17th Feb 20227:00 amRNSFull Year Trading Update
4th Feb 20227:00 amRNSKOL Investor Event on Iron Deficiency
7th Jan 20227:00 amRNSInvestor Presentation
5th Jan 20227:00 amRNSLicence Agreement in Canada for Accrufer®
30th Dec 20219:06 amRNSSecond Price Monitoring Extn
30th Dec 20219:00 amRNSPrice Monitoring Extension
29th Dec 202111:05 amRNSSecond Price Monitoring Extn
29th Dec 202111:00 amRNSPrice Monitoring Extension
16th Dec 202111:05 amRNSSecond Price Monitoring Extn
16th Dec 202111:00 amRNSPrice Monitoring Extension
16th Dec 20217:00 amRNSPatient Access Expands for Accrufer®
7th Oct 20219:45 amEQSHardman & Co Research: Shield Therapeutics (STX) Life Sciences Investor Forum research
30th Sep 20215:30 pmRNSBlock Listing 6 Monthly Return
27th Sep 20217:00 amRNSJose A. Menoyo Appointed as Chief Medical Officer
21st Sep 20217:00 amRNSInvestor presentation
23rd Aug 20217:00 amRNSPDMR Transaction Notification
20th Aug 202111:08 amEQSHardman & Co Research: Shield Therapeutics (STX) - Focused on US market penetration
17th Aug 20217:00 amRNSHalf-year Report
12th Aug 20217:25 amEQSHardman & Co Video Event | Shield Therapeutics plc - Investor Forum
12th Aug 20217:00 amRNSLicence agreement secured in Republic of Korea
11th Aug 20217:00 amRNSNotice of Results
9th Aug 20217:00 amRNSAEGIS-CKD study results published in AJKD
4th Aug 20214:41 pmRNSSecond Price Monitoring Extn
4th Aug 20214:35 pmRNSPrice Monitoring Extension
4th Aug 20212:05 pmRNSSecond Price Monitoring Extn
4th Aug 20212:00 pmRNSPrice Monitoring Extension
24th Jun 20217:00 amRNSUS launch of Accrufer® confirmed for July 1, 2021
23rd Jun 20214:40 pmRNSSecond Price Monitoring Extn
23rd Jun 20214:35 pmRNSPrice Monitoring Extension
21st Jun 20211:35 pmRNSInvestor presentation
18th Jun 20217:00 amRNSDirectorate Change
17th Jun 20212:30 pmRNSResults of 2021 Annual General Meeting
15th Jun 20216:15 pmRNSGrant of share options to the CEO
28th May 20217:00 amRNSAppointment of new Chief Executive Officer
28th May 20217:00 amRNSTotal Voting Rights
26th May 202110:35 amEQSHardman & Co Research: Shield Therapeutics (STX): Accrufer launch on schedule
21st May 20217:00 amRNSUS update
18th May 20217:00 amRNSAEGIS-H2H study results published in IBD
17th May 20217:00 amRNSCommencement of trading on the OTCQX Best Market
13th May 20213:00 pmRNS2020 Annual Report and 2021 AGM Notice
10th May 20217:00 amRNSAppointment of Two Non-Executive Directors
6th May 20211:44 pmRNSTotal Voting Rights Update
29th Apr 20217:00 amRNSPreliminary Results
22nd Apr 20217:00 amRNSNotice of Results
7th Apr 20219:33 amRNSHolding(s) in Company
7th Apr 20219:31 amRNSHolding(s) in Company
6th Apr 202111:05 amRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.